Medtronic Upgraded to Neutral by Goldman Sachs Following Strong Q2 Results, Sets $111 Price Target

miércoles, 19 de noviembre de 2025, 11:27 pm ET1 min de lectura
MDT--

Goldman Sachs upgrades Medtronic (MDT) to Neutral due to strong Q2 FY26 results and increased R&D investments. Despite valuation being below industry average, Goldman set a 12-month price target of $111. Medtronic's strategic focus on sustainable growth through enhanced R&D and SG&A investments.

Medtronic Upgraded to Neutral by Goldman Sachs Following Strong Q2 Results, Sets $111 Price Target

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios